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Abstract
Background: Transaortic (TAo) transcatheter aortic valve implantation (TAVI) is an alter-
native approach in patients considered to be at high risk for classical open surgery with poor 
peripheral vessel access. The purpose of this study was to determine the feasibility of using TAo 
access for TAVI procedures employing the Edwards SAPIEN transcatheter heart valve. The 
primary objective was to determine overall 30-day mortality.
Methods: A total of 32 patients with severe aortic valve stenosis underwent TAo-TAVI using 
Edwards SAPIEN bioprostheses. Postoperative results were collected according to the Registry 
of the Utilization Of the TAo-TAVI approach using the Edwards SAPIEN Valve (ROUTE) 
study protocol. Complications were assessed using Valve Academic Research Consortium- 
2 (VARC-2) criteria.
Results: The mean age of the population was 80.9 ± 5.2 years, with 53.1% being female. 
All patients received either the SAPIEN XT or the SAPIEN 3 bioprosthesis (Edwards Life-
sciences). Device success was achieved in 100% of cases. One (3.25%) patient subsequently 
suffered an aortic dissection and required ascending aorta replacement. Paravalvular leakage 
was absent or mild in 26 (81%) patients, and moderate in 6 (19%) patients. Other complica-
tions included permanent pacemaker implantation in 2 (6.5%), and transient post operative 
delirium in 2 (6.5%) patients. The total hospital stay was 6.7 ± 2.4 days. New York Heart 
Association class decreased significantly on follow-up. Thirty-day mortality rate was 2 (6.5%) 
patients.
Conclusions: Use of TAo access for TAVI procedures has a reasonable clinical outcome and 
is a safe alternative to the transfemoral and transapical approaches, especially for patients with 
high-risk peripheral vessel access. (Cardiol J 2015; 22, 6: 651–656)
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Introduction
The development of the transcatheter aortic 
valve implantation (TAVI) procedure by Cribier et 
al. [1] has provided a suitable alternative to open 
vale replacement surgery for elderly high risk 
patients with severe aortic stenosis [2]. Since its 
introduction, TAVI has been predominantly per-
formed using transfemoral (TF) access [3]. How-
ever, this approach disqualifies patients with severe 
peripheral atherosclerosis or physiological abnor-
malities of the vasculature [4, 5]. Alternatively, 
a transapical approach (TA-TAVI) can be employed 
[6]. Still, this route has certain limitations; it is 
not recommended in patients with chronic lung 
diseases or poor left ventricular function, and is 
associated with a risk of serious bleeding complica-
tions [7–9]. The use of transaortic (TAo) access is 
a more recently developed alternative to TA-TAVI 
and TF-TAVI [10, 11]. This involves insertion of the 
catheter via an upper reversed L ministernotomy, 
which is a safe and well-established procedure in 
classic cardiac surgery, followed by valve implanta-
tion through the ascending aorta. This approach has 
been reported to provide ample visibility for the 
surgeon and fast recovery for most patients [12]. To 
date, there have been encouraging preliminary re-
sults published with regards to TAo-TAVI, however 
more detailed information is required to assess the 
true efficacy and safety of the procedure [10]. The 
material presented herein is taken from the Polish 
arm of the Registry Of the Utilization of the TAo-
-TAVI approach using the Edwards SAPIEN Valve 
(ROUTE). This was an international, multi-center, 
prospective, observational registry carried out in 
25 sites across Europe [13].
Methods
Patient selection
From May 2013 to June 2014, 32 consecutive 
patients who were assigned by the local Heart 
Team to undergo TAo-TAVI with an Edwards SA-
PIEN XT or SAPIEN 3 transcatheter heart valve 
(THV) were enrolled into the registry. Members 
of the Heart Team included a cardiac surgeon, an 
interventional cardiologist, and a cardiologist. All 
study patients were previously disqualified from 
open heart surgery. Severe stenosis was defined 
as an aortic valve surface area less than 1.0 cm2 
and a mean transaortic gradient > 40 mm Hg, as 
determined using echocardiography examination. 
Prior to the intervention, all patients underwent 
a complete work-up, comprising physical exami-
nation, New York Heart Association (NYHA) as-
sessment, and baseline laboratory testing. Aortic 
annulus diameter, topography, and morphology of 
the ascending aorta were assessed exclusively by 
computed tomography angiography in all patients. 
Exclusion criteria were: congenital unicuspid/bi-
cuspid aortic valves; presence of any cardiac mass, 
vegetation, or suspicion of endocarditis; intoler-
ance of anticoagulation or antiplatelet therapy; and 
excessive calcification of the aorta at the planned 
access point. Postoperative results were collected 
according to the ROUTE study protocol, and com-
plications were assessed using the Valve Academic 
Research Consortium-2 (VARC-2) criteria [14].
TAo-TAVI procedure
All procedures were performed by the Heart 
Team in a hybrid operating room with an acces-
sible heart-lung machine. General anesthesia 
was used in all cases. A pacing wire was first 
introduced through the right jugular vein into the 
right ventricle. A reversed L ministernotomy was 
performed down to the second or third intercostal 
space, then the ascending aorta was exposed and 
directly palpated to find the optimal cannulation 
site. The selected location should be free of calci-
fication and at least 6 cm from the aortic annulus. 
Thereafter, two 4-0 Prolene purse-string su-
tures were placed. A bolus of intravenous heparin 
(1.5 mg/kg) was administered to obtain an activated 
clotting time of at least 250 s. A diagnostic cath-
eter was then introduced through the right radial 
artery and placed under fluoroscopic guidance in 
the non-coronary aortic sinus. Fluoroscopy was 
performed to confirm the correct puncture site and 
its position with respect to the annulus. The aortic 
wall was subsequently punctured with a needle 
to allow introduction of a 6 F sheath. Following 
this, a 6 F multipurpose catheter (MPA, Boston 
Scientific) was placed and the valve was crossed 
with a soft-tip straight wire. The soft wire was 
changed for a pre-shaped extra stiff wire placed 
in the apex of the left ventricle. The 6 F sheath 
was subsequently changed for an ASCENDRA 2 
delivery system (Edwards Lifesciences, Irvine, CA; 
22 F sheath for 23- and 26-mm valves and 26 F for 
29-mm valve). Pre-dilatation with a balloon was 
performed under rapid pacing. Finally, the valve 
was introduced through the delivery system after 
careful positioning in the annulus. The position 
of the prosthesis was confirmed using a dose of 
contrast medium. The valve was deployed under 
rapid pacing using a 2-step inflation technique, with 
a second shot of contrast to ensure an accurate final 
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position. After implantation, a further bolus of con-
trast was given to assess the position of the THV 
and allow simultaneous estimation of paravalvular 
leakage (PVL) and coronary status. The decision 
of whether to carry out post-dilatation was made 
after estimating the shape of the valve and after 
quantification of PVL.
Echocardiography
Each patient underwent transesophageal echo-
cardiography (TEE) assessment at least 3 times 
throughout their hospital course: on admission; 
post-procedurally to estimate PVL, contractility of 
the left ventricle, and to assess pericardial effusion; 
and at discharge.
Follow-up, complications, and mortality
A 30-day follow-up was conducted in an out-
patient clinic setting. Events occurring within the 
1st month were considered to procedure-related 
and as such, were documented. Complication rates 
were recorded according to the VARC-2 criteria. 
Thirty-day mortality was defined as all-cause 
mortality during hospitalization or within 30 days 
of admission.
Statistical analyses
Statistical analyses were performed using the 
statistical suite StatSoft, Inc. (2011; STATISTICA 
data analysis software system version 10.0) and 
Microsoft Excel. Quantitative variables are given 
as the arithmetic mean and standard deviation, or 
median with range and 95% confidence interval 
(CI). Qualitative variables are presented as abso-
lute values and percentages.
Results
Population characteristics
The study population consisted of 32 patients, 
of which 17 were female (53.1%; Table 1). The 
mean age was 80.9 ± 5.2 years, with a mean height 
of 164.6 ± 11.1 cm, and mean weight of 74.7 ± 
± 16.0 kg. The EuroSCORE range was 1–11% 
(mean 2.84%) with mean Society Thoracic Sur-
geons score of 8.7% (range 2–19%). A small pro-
portion of patients suffered moderate mitral valve 
insufficiency (9.4%), while 59.4% suffered mild, 
and 31.3% suffered none. Comorbidities within 
the population were frequent, with hypertension 
being the most prevalent at 87.5%. The other most 
common conditions were coronary artery disease 
(59.4%), diabetes mellitus (15.6%), myocardial 
infarction (12.5%), and atrial fibrillation (12.5%). 
Patients who were also suitable for other access 
routes were also included in the study, with TF 
access judged to be possible for 87.5% of them.
Echocardiographic findings prior  
to the intervention
Prior to the TAo-TAVI procedure, the mean 
ejection fraction was measured to be 57.9 ± 9.0% 
(Table 2). The peak pressure gradient was 78.9 ± 
± 23.3 mm Hg, with a mean pressure gradient of 
48.3 ± 14.4 mm Hg. The mean maximal velocity 
(Vmax) of the population was 4.3 ± 0.6 m/s.
Procedural characteristics
The majority of patients underwent implan-
tation of the SAPIEN XT THV (93.8%), with the 
remaining procedures being carried out using the 
more recently approved SAPIEN 3 (7.2%; Table 3). 
The mean duration of the procedure, defined as the 
time from the first skin incision until completion 
of the final suture, was 96.7 ± 34.8 min. The mean 
Table 2. Echocardiographic findings (n = 32).
Ejection fraction [%] 57.9 ± 9.0
Peak PG [mm Hg] 78.9 ± 23.3
Mean PG [mm Hg] 48.3 ± 14.4
Vmax [m/s] 4.3 ± 0.6 
PG — pressure gradient; Vmax — maximal velocity
Table 1. Patient characteristics (n = 32).
Age [years] 80.9 ± 5.2
Female gender 17 (53.1%)
Height [cm] 164.6 ± 11.1
Weight [kg] 74.7 ± 16.0
Mitral insufficiency:
None 10 (31.3%)
Mild 19 (59.4%)
Moderate 3 (9.4%)
Comorbidities:
Coronary artery disease 19 (59.4%)
Myocardial infarction 4 (12.5%)
PCI (prior 6 weeks) 1 (3.1%)
Atrial fibrillation 4 (12.5%)
Hypertension 28 (87.5%)
Diabetes mellitus 5 (15.6%)
Stroke 2 (6.2%)
COPD 3 (9.4%) 
PCI — percutaneous coronary intervention; COPD — chronic  
obstructive pulmonary disease
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volume of contrast agent used was 119.9 ± 35.7 mL, 
and the mean fluoroscopy time was 14.7 ± 7.1 min, 
which included positioning of the pacing wires. 
Post-dilatation was carried out in 8 (25%) cases.
Follow-up
Paravalvular leakage was classified as none 
to trace in 11 (34%) patients, mild in 15 (47%), 
and moderate in 6 (19%) patients. The mean peak 
pressure gradient was significantly reduced from 
78.9 ± 23.3 mm Hg before TAVI to 9.4 ± 2.9 mm Hg 
after, with the mean Vmax decreasing from 4.3 ± 
± 0.6 m/s to 2.1 ± 0.3 m/s. After the procedure, the 
mean creatinine level was found to be 1.5 ± 1.3 mg/dL 
(Table 4). Permanent atrioventricular (AV) block 
occurred in 2 (6.5%) cases, with both requiring 
peacemaker implantation. The mean duration of 
hospital stay was 6.7 ± 2.4 days, with the majority 
of patients (59.4%) being discharged home. Two 
(6.5%) patients died during the 30-day follow-up 
period, both due to respiratory complications. 
Quality of life improvement was best evidenced by 
significant decreases in the proportion of patients 
with angina pectoris at Canadian Cardiovascular 
Society class III/IV and heart failure at NYHA class 
III/IV (Fig. 1).
Discussion
The direct transaortic approach for TAVI is 
a more recently developed alternative to the use 
of TA access in patients for whom the TF route 
is contraindicated [10]. In early reports, Clarke 
et al. [11] found good ease of access and visibility 
using this method, while Lardizabal et al. [15] 
demonstrated superior mortality rates compared 
to the TA approach, with comparable complication 
rates. The short distance from the puncture site 
to the annulus enabled by the TAo access provides 
excellent and immediate tactile feedback [16]. 
This short delivery system is easy to navigate and 
gives consistent confidence in accurate prosthesis 
positioning [17]. Furthermore, it avoids the aortic 
Table 3. Procedural characteristics (n = 32).
Valve type used:
SAPIEN XT 30 (93.8%)
SAPIEN 3 2 (7.2%)
Valve size:
23 mm 11 (34%)
26 mm 8 (25%)
29 mm 13 (40%)
Skin-to-skin time [min] 96.7 (34.8%)
Volume of contrast [mL] 119.9 ± 35.7
Fluoroscopy time [min] 14.7 ± 7.1
Post-dilatation 8 (25.0%)
Table 4. Procedural outcomes (n = 32).
Paravalvular leakage:
None to trace 11 (34%)
Mild 15 (47%)
Moderate 6 (19%)
Severe 0 (0.0%)
Creatinine level [mg/dL] 1.5 (1.3)
Atrioventricular block 2 (6.5%)
Pacemaker implantation 2 (6.5%)
Aortic dissection 1 (3.1%)
Transient post operative delirium 2 (6.5%)
Hospital stay [days] 6.7 ± 2.4
Discharged home 19 (59.4%)
30-day mortality 2 (6.5%)
Figure 1. Changes in grading of angina pectoris and 
heart failure; A. Canadian Cardiovascular Society (CCS); 
B. New York Heart Association (NYHA); TAVI — trans-
catheter aortic valve implantation.
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arch, and is therefore less likely to be associated 
with neurological complications caused by calcific 
debris, as is sometimes seen with the TF approach. 
Injury to the subvalvular apparatus of the mitral 
valve, ventricular septal defects, and development 
of a false aneurysm of the apex of the left ventricle 
are all well-described complications of the TA ap-
proach that are not associated with TAo-TAVI [6]. 
Furthermore, major bleeding occurs infrequently in 
the latter; however, should such a serious compli-
cation occur intraoperatively, the ministernotomy 
may be easily converted to full sternotomy, provid-
ing instant access to the aortic root [5].
In our series, any PVL after the TAo-TAVI pro-
cedure was regarded as trace or mild, with a small 
proportion of patients experiencing that classed as 
moderate. There were no cases of severe leakage, 
which is similar to previously reported results 
[5, 18, 19]. This demonstrates the accurate valve 
positioning that is possible using this procedure.
In terms of complications, 1 patient suffered 
from aortic dissection, which was diagnosed im-
mediately after valve deployment. A success-
ful ascending aorta replacement was performed 
without removal of the otherwise well-positioned 
SAPIEN prosthesis. We observed no major strokes 
in our group of patients and only 2 patients suf-
fered from transient ischemia. The most prevalent 
complication was the development of AV block with 
a requirement for pacemaker implantation, which 
is in agreement with previous studies regarding 
TAo-TAVI [20, 21]. In contrast, for the TA approach, 
this complication has been shown to occur less 
frequently [21–23], indicating that positioning of 
the THV may be deeper when the TAo route is 
used [24, 25].
All-cause mortality during the 30-day follow-
up period was similar to that reported for other 
TAo-TAVI studies [18, 20]. Furthermore, it was 
significantly lower than values documented for 
TA-TAVI [3, 15, 22].
Limitations of the study
Whilst these data demonstrate the potential 
of TAo-TAVI as an alternative to TF and TA, there 
were a number of limitations. Firstly, all patients 
were operated on in the same center by the same 
Heart Team. Secondly, owing to the small number 
of SAPIEN 3 valves employed, it was not possible 
to directly compare the outcomes between these 
and the SAPIEN XT.
Conclusions
The use of TAo access for TAVI procedures 
provides a satisfactory clinical outcome and is a safe 
alternative for patients with poor peripheral ves-
sel access and common comorbidities. This study 
shows the TAo approach to be a very promising 
prospective for the future. Our findings provide 
some insight into the further developments and 
investigation required in this growing area.
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